Barr Barred From Premarin Equine-Based Generics; ANDA Status Under Review
Executive Summary
Barr Labs will meet with FDA to discuss the status of its conjugated estrogens ANDA following a district court decision barring the company from using Natural Biologics' raw material for an "AB"-rated generic